|
1
|
Fearon K, Strasser F, Anker SD, Bosaeus I,
Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N,
Mantovani G, et al: Definition and classification of cancer
cachexia: An international consensus. Lancet Oncol. 12:489–495.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tan BH and Fearon KC: Cachexia: Prevalence
and impact in medicine. Curr Opin Clin Nutr Metab Care. 11:400–407.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tisdale MJ: Mechanisms of cancer cachexia.
Physiol Rev. 89:381–410. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Russell ST, Sanders PM and Tisdale MJ:
Angiotensin II directly inhibits protein synthesis in murine
myotubes. Cancer Lett. 231:290–294. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sanders PM, Russell ST and Tisdale MJ:
Angiotensin II directly induces muscle protein catabolism through
the ubiquitin-proteasome proteolytic pathway and may play a role in
cancer cachexia. Br J Cancer. 93:425–434. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ruiz-Ortega M, Lorenzo O, Suzuki Y,
Rupérez M and Egido J: Proinflammatory actions of angiotensins.
Curr Opin Nephrol Hypertens. 10:321–329. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang L, Du J, Hu Z, Han G, Delafontaine
P, Garcia G and Mitch WE: IL-6 and serum amyloid A synergy mediates
angiotensin II-induced muscle wasting. J Am Soc Nephrol.
20:604–612. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Russell ST, Eley H and Tisdale MJ: Role of
reactive oxygen species in protein degradation in murine myotubes
induced by proteolysis-inducing factor and angiotensin II. Cell
Signal. 19:1797–1806. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sukhanov S, Semprun-Prieto L, Yoshida T,
Michael Tabony A, Higashi Y, Galvez S and Delafontaine P:
Angiotensin II, oxidative stress and skeletal muscle wasting. Am J
Med Sci. 342:143–147. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dalla Libera L, Ravara B, Angelini A,
Rossini K, Sandri M, Thiene G, Battista Ambrosio G and Vescovo G:
Beneficial effects on skeletal muscle of the angiotensin II type 1
receptor blocker irbesartan in experimental heart failure.
Circulation. 103:2195–2200. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Neo JH, Ager EI, Angus PW, Zhu J, Herath
CB and Christophi C: Changes in the renin angiotensin system during
the development of colorectal cancer liver metastases. BMC Cancer.
10:1342010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sun G, Haginoya K, Dai H, Chiba Y, Uematsu
M, Hino-Fukuyo N, Onuma A, Iinuma K and Tsuchiya S: Intramuscular
renin-angio-tensin system is activated in human muscular dystrophy.
J Neurol Sci. 280:40–48. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang XH and Mitch WE: Mechanisms of muscle
wasting in chronic kidney disease. Nat Rev Nephrol. 10:504–516.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Murphy KT, Chee A, Trieu J, Naim T and
Lynch GS: Inhibition of the renin-angiotensin system improves
physiological outcomes in mice with mild or severe cancer cachexia.
Int J Cancer. 133:1234–1246. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Q, Li C, Peng X, Kang Q, Deng D,
Zhang L, Zheng Y, Wang C, Qiao Z, Guo D, et al: Combined treatment
of carfilzomib and z-VAD-fmk inhibits skeletal proteolysis and
apoptosis and ameliorates cancer cachexia. Med Oncol. 32:1002015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Acharyya S and Guttridge DC: Cancer
cachexia signaling pathways continue to emerge yet much still
points to the proteasome. Clin Cancer Res. 13:1356–1361. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Penna F, Baccino FM and Costelli P: Coming
back: Autophagy in cachexia. Curr Opin Clin Nutr Metab Care.
17:241–246. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Del Fiorentino A, Cianchetti S, Celi A and
Pedrinelli R: Aliskiren, a renin inhibitor, downregulates
TNF-α-induced tissue factor expression in HUVECS. J Renin
Angiotensin Aldosterone Syst. 11:243–247. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Patel RB, Prajapati KD, Sonara BM, Sharma
MM, Patel HM, Pawar VD and Jain MR: Ameliorative potential of
aliskiren in experimental colitis in mice. Eur J Pharmacol.
737:70–76. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schmerbach K, Pfab T, Zhao Y, Culman J,
Mueller S, Villringer A, Muller DN, Hocher B, Unger T and
Thoene-Reineke C: Effects of aliskiren on stroke in rats expressing
human renin and angiotensinogen genes. PLoS One. 5:e150522010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
De Luca A, Pierno S, Liantonio A, Cetrone
M, Camerino C, Fraysse B, Mirabella M, Servidei S, Rüegg UT and
Conte Camerino D: Enhanced dystrophic progression in mdx mice by
exercise and beneficial effects of taurine and insulin-like growth
factor-1. J Pharmacol Exp Ther. 304:453–463. 2003. View Article : Google Scholar
|
|
22
|
Ham DJ, Murphy KT, Chee A, Lynch GS and
Koopman R: Glycine administration attenuates skeletal muscle
wasting in a mouse model of cancer cachexia. Clin Nutr. 33:448–458.
2014. View Article : Google Scholar
|
|
23
|
Murphy KT, Chee A, Trieu J, Naim T and
Lynch GS: Importance of functional and metabolic impairments in the
characterization of the C-26 murine model of cancer cachexia. Dis
Model Mech. 5:533–545. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tanaka Y, Eda H, Tanaka T, Udagawa T,
Ishikawa T, Horii I, Ishitsuka H, Kataoka T and Taguchi T:
Experimental cancer cachexia induced by transplantable colon 26
adenocarcinoma in mice. Cancer Res. 50:2290–2295. 1990.PubMed/NCBI
|
|
26
|
Guo CB, Zhang W, Ma DQ, Zhang KH and Huang
JQ: Hand grip strength: An indicator of nutritional state and the
mix of postoperative complications in patients with oral and
maxillofacial cancers. Br J Oral Maxillofac Surg. 34:325–327. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Carson JA and Baltgalvis KA: Interleukin 6
as a key regulator of muscle mass during cachexia. Exerc Sport Sci
Rev. 38:168–176. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Deans C and Wigmore SJ: Systemic
inflammation, cachexia and prognosis in patients with cancer. Curr
Opin Clin Nutr Metab Care. 8:265–269. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tsoli M and Robertson G: Cancer cachexia:
Malignant inflammation, tumorkines, and metabolic mayhem. Trends
Endocrinol Metab. 24:174–183. 2013. View Article : Google Scholar
|
|
30
|
Vaughan VC, Martin P and Lewandowski PA:
Cancer cachexia: Impact, mechanisms and emerging treatments. J
Cachexia Sarcopenia Muscle. 4:95–109. 2013. View Article : Google Scholar :
|
|
31
|
Thomas CM, Yong QC, Seqqat R, Chandel N,
Feldman DL, Baker KM and Kumar R: Direct renin inhibition prevents
cardiac dysfunction in a diabetic mouse model: Comparison with an
angiotensin receptor antagonist and angiotensin-converting enzyme
inhibitor. Clin Sci (Lond). 124:529–541. 2013. View Article : Google Scholar
|
|
32
|
Penna F, Costamagna D, Pin F, Camperi A,
Fanzani A, Chiarpotto EM, Cavallini G, Bonelli G, Baccino FM and
Costelli P: Autophagic degradation contributes to muscle wasting in
cancer cachexia. Am J Pathol. 182:1367–1378. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tardif N, Klaude M, Lundell L, Thorell A
and Rooyackers O: Autophagic-lysosomal pathway is the main
proteolytic system modified in the skeletal muscle of esophageal
cancer patients. Am J Clin Nutr. 98:1485–1492. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
McClung JM, Judge AR, Powers SK and Yan Z:
p38 MAPK links oxidative stress to autophagy-related gene
expression in cachectic muscle wasting. Am J Physiol Cell Physiol.
298:C542–C549. 2010. View Article : Google Scholar :
|
|
35
|
Rahman M, Mofarrahi M, Kristof AS,
Nkengfac B, Harel S and Hussain SN: Reactive oxygen species
regulation of autophagy in skeletal muscles. Antioxid Redox Signal.
20:443–459. 2014. View Article : Google Scholar
|
|
36
|
Weng LQ, Zhang WB, Ye Y, Yin PP, Yuan J,
Wang XX, Kang L, Jiang SS, You JY, Wu J, et al: Aliskiren
ameliorates pressure overload-induced heart hypertrophy and
fibrosis in mice. Acta Pharmacol Sin. 35:1005–1014. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang W, Zhao G, Hu X, Wang M, Li H, Ye Y,
Du Q, Yao J, Bao Z, Hong W, et al: Aliskiren-attenuated myocardium
apoptosis via regulation of autophagy and connexin-43 in aged
spontaneously hypertensive rats. J Cell Mol Med. 18:1247–1256.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Burckart K, Beca S, Urban RJ and
Sheffield-Moore M: Pathogenesis of muscle wasting in cancer
cachexia: Targeted anabolic and anticatabolic therapies. Curr Opin
Clin Nutr Metab Care. 13:410–416. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yuan L, Han J, Meng Q, Xi Q, Zhuang Q,
Jiang Y, Han Y, Zhang B, Fang J and Wu G: Muscle-specific E3
ubiquitin ligases are involved in muscle atrophy of cancer
cachexia: An in vitro and in vivo study. Oncol Rep. 33:2261–2268.
2015.PubMed/NCBI
|
